QBX-258 / Novartis - LARVOL DELTA

Pilot Study of Anti-Th2 Immunotherapy for the Treatment of Breast Cancer-Related Upper Extremity Lymphedema. (PubMed, Biology (Basel)) - "The aim of this study was to test the efficacy of QBX258, a monoclonal IL4/IL13 neutralizing antibody, in women with breast cancer-related lymphedema (BCRL)...Our limited study suggests that immunotherapy against Th2 cytokines may improve skin changes and QOL of women with BCRL. This treatment appears to be less effective for decreasing limb volumes; however, additional studies are needed."

Clinical • IO biomarker • Journal • Breast Cancer • Dermatology • Immunology • Inflammation • Oncology • Solid Tumor • IL13 • IL4

Immunotherapy for the Treatment of Breast Cancer Related Upper Extremity Lymphedema (BCRL) (clinicaltrials.gov) - P=N/A; N=22; Recruiting; Sponsor: Memorial Sloan Kettering Cancer Center

New trial • Biosimilar • Breast Cancer • Oncology • Triple Negative Breast Cancer